Cardiff Oncology, Inc. (NASDAQ:CRDF) CFO James E. Levine purchased 30,000 shares of the business’s stock in a transaction on Friday, September 10th. The stock was acquired at an average cost of $6.47 per share, with a total value of $194,100.00. Following the completion of the acquisition, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $32,350. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of NASDAQ CRDF opened at $6.51 on Wednesday. The stock has a market cap of $257.48 million, a PE ratio of -9.43 and a beta of 1.78. The business has a fifty day moving average of $6.14 and a two-hundred day moving average of $7.89. Cardiff Oncology, Inc. has a 52-week low of $4.88 and a 52-week high of $25.50.
Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.07 million. Cardiff Oncology had a negative net margin of 5,830.38% and a negative return on equity of 21.65%. Equities analysts forecast that Cardiff Oncology, Inc. will post -0.68 EPS for the current year.
A number of equities analysts recently commented on the company. Zacks Investment Research downgraded Cardiff Oncology from a “buy” rating to a “hold” rating in a report on Thursday, August 12th. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Cardiff Oncology in a research report on Thursday, September 9th. Finally, Maxim Group raised their target price on Cardiff Oncology from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, September 9th.
About Cardiff Oncology
Cardiff Oncology, Inc is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
Featured Story: Dual Listing What You Need to Know
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.